# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G Under the Securities Exchange Act of 1934

# ESPERION THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE \$0.001 PER SHARE (Title of Class of Securities) 29664W105 (CUSIP Number) JUNE 10, 2024

(Date of event which requires filing of this statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☑ Rule 13d-1(c)

☐ Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).

CUSIP 1	No. 29664W105		SCHEDULE 13G	Page 2 of 10					
1	NAMES OF REPORTING		TS .						
	Millennium Management LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP								
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (a) □  (b) □								
3	SEC USE ONLY								
	CITIZENSHIP OR PLAC	E OF ORC	GANIZATION						
4	Delaware								
	NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5 6 7 8	SOLE VOTING POWER  -0- SHARED VOTING POWER  10,176,529  SOLE DISPOSITIVE POWER  -0- SHARED DISPOSITIVE POWER						
			10,176,529						
9	AGGREGATE AMOUNT 10,176,529	T BENEFIC	CIALLY OWNED BY EACH REPORTING PERSON						
	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES								

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

TYPE OF REPORTING PERSON

12

00

CUSIP N	Jo. 29664W105		SCHEDULE 13G	Page	3	of		10
1	NAMES OF REPORTING F							
2			IF A MEMBER OF A GROUP					
3	SEC USE ONLY							
4	CITIZENSHIP OR PLACE OF ORGANIZATION  Delaware							
		5	SOLE VOTING POWER -0-					
	NUMBER OF SHARES BENEFICIALLY OWNED BY	6	E VOTING POWER  RED VOTING POWER  76,529					
	EACH REPORTING PERSON WITH	7	SOLE DISPOSITIVE POWER -0-					
	TERSON WITH		SHARED DISPOSITIVE POWER					

9	
	10,176,529
	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
10	
	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11	
	5.4%
	TYPE OF REPORTING PERSON
12	

10,176,529
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

CUSIP No.	29664W105	SCHEDULE 13G	Page	4	of	10

1	NAMES OF REPORTING	PERSON	S				
1	Israel A. Englander						
		TE BOX	IF A MEMBER OF A GROUP				
2	(a) □ (b) □						
3	SEC USE ONLY						
	CITIZENSHIP OR PLACE	OF ORC	GANIZATION				
4	United States						
			SOLE VOTING POWER				
		5					
	NUMBER OF		-0-				
	SHARES	6	SHARED VOTING POWER				
	BENEFICIALLY OWNED BY	°	10,176,529				
	EACH	7	SOLE DISPOSITIVE POWER				
	REPORTING PERSON WITH		-0-				
		8	SHARED DISPOSITIVE POWER				
			10,176,529				
	AGGREGATE AMOUNT F	3ENEFIC	CIALLY OWNED BY EACH REPORTING PERSON				
9	10,176,529						
	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
10	_						
	DED CENTE OF CLASS DEL	DECEN	EED DV AMOUNTE BUDOW (0)				
11	PERCENT OF CLASS REF	RESEN	TED BY AMOUNT IN ROW (9)				
''	5.4%						
	TYPE OF REPORTING PE	RSON					
12	IN						

CUSIP No		29664W105 SCHEDULE 13G	Page
Item 1.	(a)	Name of Issuer:	
		Esperion Therapeutics, Inc.	
	(b)	Address of Issuer's Principal Executive Offices:	
		3891 Ranchero Drive, Suite 150 Ann Arbor, Michigan 48108	
Item 2.	(a) (b) (c)	Address of Principal Business Office:	
		Millennium Management LLC 399 Park Avenue New York, New York 10022 Citizenship: Delaware	
		Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Citizenship: Delaware	
		Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Citizenship: United States	
	(d)	<u>Title of Class of Securities</u> :	
		common stock, par value \$0.001 per share ("Common Stock")	
	(e)	CUSIP Number:	
		29664W105	
Item 3. If	this stat	ement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:	
(a)		Broker or dealer registered under section 15 of the Act (15 U.S.C. 780);	
(b)		Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);	
(c)		Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);	
(d)		Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 8	0a-8);
(e)		An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);	

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(f)

5 of 10

CUSIP No.		29664W105	SCHEDULE 13G	Page	6	of	10			
(g)		A parent holding comp	any or control person in accordance with §240.13d-1(b)(1)(ii)(G);							
(h)		A savings association a	savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);							
(i)			a church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 940 (15 U.S.C. 80a-3);							
(j)		Group, in accordance v	rith §240.13d-1(b)(1)(ii)(J).							
Item 4. Owr	nership	<u>)</u>								
Provide th	Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.									
(a) Amount	(a) Amount Beneficially Owned:									

See response to Item 9 on each cover page.

### (b) Percent of Class:

See response to Item 11 on each cover page.

### (c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote

See response to Item 5 on each cover page.

CUSIP No.	29664W105	SCHEDULE 13G	Page	7	of	10
-----------	-----------	--------------	------	---	----	----

(ii) Shared power to vote or to direct the vote

See response to Item 6 on each cover page.

(iii) Sole power to dispose or to direct the disposition of

See response to Item 7 on each cover page.

(iv) Shared power to dispose or to direct the disposition of

See response to Item 8 on each cover page.

The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

### Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  $\Box$ .

### Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

### Item 8. Identification and Classification of Members of the Group

See Exhibit I.

### Item 9. Notice of Dissolution of Group

Not applicable.

### Item 10. Certification

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 29664W105 SCHEDULE 13G Page 8 of 10

Exhibits:

Exhibit I: Joint Filing Agreement, dated as of June 11, 2024, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

CUSIP No. 29664W105 SCHEDULE 13G Page 9 of 10

### **SIGNATURE**

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

Dated: June 11, 2024

MILLENNIUM MANAGEMENT LLC

By: /s/Gil Raviv

Name: Gil Raviv

Title: Global General Counsel

MILLENNIUM GROUP MANAGEMENT LLC

By: /s/Gil Raviv

Name: Gil Raviv

Title: Global General Counsel

/s/ Israel A. Englander

Israel A. Englander

## CUSIP No. 29664W105 SCHEDULE 13G Page 10 of 10

### EXHIBIT I

### JOINT FILING AGREEMENT

This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value \$0.001 per share, of Esperion Therapeutics, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Dated: June 11, 2024

MILLENNIUM MANAGEMENT LLC

By: /s/Gil Raviv

Name: Gil Raviv

Title: Global General Counsel

MILLENNIUM GROUP MANAGEMENT LLC

By: /s/Gil Raviv

Name: Gil Raviv

Title: Global General Counsel

/s/ Israel A. Englander

Israel A. Englander